INS and type 2 diabetes mellitus: These observations in primary human macrophage and skeletal myotubes may offer an explanation for the increased insulin sensitivity following treatment with the HDL-raising agent, torcetrapib, a CETP inhibitor in patients with type 2 diabetes [1].